<DOC>
	<DOCNO>NCT01747642</DOCNO>
	<brief_summary>Oncoxin combination Surafenib safe result improve survival patient hepatocellular carcinoma ( HCC )</brief_summary>
	<brief_title>Safety Efficacy Oncoxin Plus Surafineb Hepatocellular Carcinoma</brief_title>
	<detailed_description>To assess therapeutic efficacy safety Oncoxin plus Surafenib hepatocellular carcinoma To see reduction serum alpha fetoprotein level hepatocellular carcinoma patient administration Oncoxin plus Surafenib To see reduction tumor size number hepatocellular carcinoma patient administration Oncoxin plus Surafenib To see improvement quality life hepatocellular carcinoma patient administration Oncoxin plus Surafenib To see improved survival hepatocellular carcinoma patient administration Oncoxin plus Surafenib</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients HCC irrespective etiology , age , gender status underlie liver disease . Patients HCC suitable candidate establish modality treatment i.e . surgery and/or chemotherapy . Patients HCC evidence tumor metastasis Patients HCC voluntarily unwilling take establish modality treatment i.e . surgery and/or chemotherapy . Patients HCC possible treatment option exhaust . Patients HCC suitable candidate establish modality treatment i.e . surgery and/or chemotherapy . Patients HCC evidence tumor metastasis Patients HCC willing take establish modality treatment i.e . surgery and/or chemotherapy . Patients HCC voluntarily unwilling include trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Oncoxin</keyword>
	<keyword>Surafenib</keyword>
</DOC>